menu search

Chevron: a capital return record that speaks for itself

Despite their decline in market cap, oil majors like Chevron still have significant physical assets and revenue streams that rival many large tech fir...

July 11, 2023, 6:47 pm

Takeda withdraws us application for dengue vaccine candidate

Takeda Pharmaceutical Co said on Tuesday it was voluntarily withdrawing its application for its dengue vaccine ...

July 11, 2023, 11:32 am

Nanoviricides reveals promising efficacy of its antiviral drug candidate in combating rsv

NanoViricides Inc (NYSE-A:NNVC) has announced the promising efficacy of its antiviral drug candidate N...

July 11, 2023, 8:17 am

Genelux: a game changer in platinum-resistant ovarian cancer

Genelux, an immuno-oncology frontrunner, has secured over $65 million in financing and is conducting successful clinical trials for its primary ...

July 11, 2023, 4:12 am

Ipo update: apogee therapeutics proposes terms for $250 million ipo

Apogee Therapeutics, Inc. has filed proposed terms for a $250 million IPO. The firm is developing drug treatment ...

July 10, 2023, 5:33 pm

Viking therapeutics (vktx) surges 64% year to date: here's why

The rising share price of Viking Therapeutics (VKTX) is attributable to the successful development of the company's pipeline ...

July 10, 2023, 11:00 am

Kalvista (kalv) surges 15% on update from angioedema study

KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, se...

July 10, 2023, 11:00 am

International wide-moat stocks on sale - the july 2023 heat map

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in ...

July 7, 2023, 11:07 am

U.s. wide-moat stocks on sale - the july 2023 heat map

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in ...

July 6, 2023, 9:31 am

‘the corpse of bitcoin’: crypto skeptic’s appointment to central bank casts doubt on china warming to digital assets

In an unusually candid speech at an event in 2017, Pan quoted a study by French professor Eric Clichet ...

July 5, 2023, 5:44 pm

Genprex granted chinese patent for lead drug candidate reqorsa with pd-1 antibodies to treat cancers

Genprex Inc. revealed that the China National Intellectual Property Administration has granted it a broad patent, which covers the use of its lead dru...

July 5, 2023, 9:47 am

Verve: exciting deal with eli lilly, but still neutral (reiterating hold)

Verve Therapeutics announced a partnership with Eli Lilly & Co., focusing on in-vivo gene editing technology, but investors remain concerned about the...

July 4, 2023, 4:57 am

Down 80% in 1 day, is there any hope for fibrogen stock?

FibroGen's lead candidate whiffed twice in June. It has a significant chance of reporting more unfavora...

July 1, 2023, 8:46 am

Pfizer just canned one of its ozempic killers. what's next?

Pfizer discontinued one of its candidates to treat diabetes and obesity. Even if it hadn't been discont...

July 1, 2023, 7:55 am

Home depot can likely beat expectations if recession is avoided

Home Depot (HD) is a quintessential blue-chip stock that is currently at a reasonable valuation and has had expectations reduced after COVID demand wa...

July 1, 2023, 3:58 am

Autolus therapeutics could hold a winning car t-cell ticket

Obe-cel and pipeline offer many catalysts in 2023. The CAR T-cell candidate offer a safer alternative t...

June 30, 2023, 7:34 pm

Kintara (ktra) rises 41% on $2m grant for breast cancer therapy

Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment ...

June 30, 2023, 12:12 pm

Baudax bio shares jump on acquisition of teraimmune

Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech d...

June 30, 2023, 8:18 am

Liquidia (lqda) up on deal with pharmosa to co-develop ph drug

Liquidia (LQDA) signs an exclusive licensing agreement with Pharmosa to jointly develop and commercialize PAH and PH-ILD treatment ...

June 29, 2023, 12:54 pm

Is bluebird bio stock a buy now?

Bluebird's approved treatments still are not generating much by way of sales. The company's next candid...

June 29, 2023, 7:45 am


Search within

Pages Search Results: